Skip to main content

IgG4-related Disease

5
Pipeline Programs
3
Companies
10
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
1
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 8 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
7 programs
1
1
2
Prednisone and BelimumabPhase 4Monoclonal Antibody1 trial
T 614Phase 41 trial
PrednisonePhase 2/31 trial
68Ga-FAPIPhase 11 trial
A Prospective Cohort Study of IgG4RD in ChinaN/A1 trial
+2 more programs
Active Trials
NCT01670695Recruiting1,000Est. Jan 2032
NCT03023371Recruiting900Est. Dec 2026
NCT06663618Recruiting63Est. Sep 2025
+4 more trials
Acepodia
AcepodiaCA - Alameda
1 program
1
ACE1831Phase 1/22 trials
Active Trials
NCT07061938Recruiting30Est. Jun 2027
NCT05653271Recruiting42Est. Sep 2027
Bristol Myers Squibb
1 program
AbataceptPHASE_21 trial
Active Trials
NCT03669861Completed10Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsPrednisone and Belimumab
UNION therapeuticsT 614
UNION therapeuticsPrednisone
Bristol Myers SquibbAbatacept
AcepodiaACE1831
AcepodiaACE1831
UNION therapeutics68Ga-FAPI
UNION therapeuticsprednison
UNION therapeuticsNational Registry of IgG4-RD in China
UNION therapeuticsA Prospective Cohort Study of IgG4RD in China

Clinical Trials (10)

Total enrollment: 2,275 patients across 10 trials

NCT04660565UNION therapeuticsPrednisone and Belimumab

Belimumab Treatment for IgG4-related Disease

Start: Jan 2021Est. completion: Dec 202360 patients
Phase 4Unknown
NCT03368274UNION therapeuticsT 614

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom

Start: Sep 2017Est. completion: Jun 201830 patients
Phase 4Unknown
NCT01758393UNION therapeuticsPrednisone

Glucocorticoids in Patients With IgG4-RD

Start: Dec 2012Est. completion: Apr 201440 patients
Phase 2/3Unknown
NCT03669861Bristol Myers SquibbAbatacept

Safety and Efficacy of Abatacept in IgG4-Related Disease

Start: Nov 2018Est. completion: Nov 202010 patients
Phase 2Completed
NCT07061938AcepodiaACE1831

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Start: Jan 2026Est. completion: Jun 202730 patients
Phase 1/2Recruiting
NCT05653271AcepodiaACE1831

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Start: Jan 2023Est. completion: Sep 202742 patients
Phase 1Recruiting
NCT04125511UNION therapeutics68Ga-FAPI

Characterizing IgG4-RD With 68Ga-FAPI PET/CT

Start: Nov 2019Est. completion: Dec 2021100 patients
Phase 1Unknown
NCT06663618UNION therapeuticsprednison

Short-term Glucocorticoid Combined with MMF for IgG4-RD

Start: Sep 2023Est. completion: Sep 202563 patients
N/ARecruiting
NCT03023371UNION therapeuticsNational Registry of IgG4-RD in China

National Registry of IgG4-RD in China

Start: Dec 2016Est. completion: Dec 2026900 patients
N/ARecruiting
NCT01670695UNION therapeuticsA Prospective Cohort Study of IgG4RD in China

A Prospective Cohort Study of IgG4RD in China

Start: Jan 2012Est. completion: Jan 20321,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 actively recruiting trials targeting 2,275 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.